Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10071/23017
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | de Mello-Sampayo, F. | - |
dc.contributor.author | Fiuza, M. | - |
dc.contributor.author | Pinto, F. | - |
dc.contributor.author | Fonte, J. | - |
dc.date.accessioned | 2021-08-10T10:22:39Z | - |
dc.date.available | 2021-08-10T10:22:39Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0870-2551 | - |
dc.identifier.uri | http://hdl.handle.net/10071/23017 | - |
dc.description.abstract | Introduction Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness study analyzes cardio-oncology imaging assessment of left ventricular ejection fraction (LVEF) using a Portuguese healthcare payer perspective and a five-year time horizon. Methods Two cardioprotective strategies were assessed: universal cardioprotection (UCP) for all patients and cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX). A Markov model, informed by the retrospective clinical course of breast cancer patients followed in a Portuguese public hospital, was developed to assess the cost-effectiveness of LVEF cardio-oncology imaging assessment. Data on transition probabilities, costs and utilities were retrieved from both the retrospective data and published literature to assess the cost-effectiveness of LVEF echocardiographic assessment. Costs and utilities of the cardioprotective strategies were assessed over a five-year range, using probabilistic sensitivity analyses. Results In the reference case of a 63-year-old breast cancer patient treated with cardioprotection initiated on diagnosis of EF-CTX, the five-year time horizon (4.22 QALYs and €2594 cost over five years) dominated UCP (3.42 QALYS and €3758 cost over five years). Under a time horizon of five years at a willingness-to-pay threshold of €22 986, over 65.7% of simulations provided additional QALYs. Monte Carlo simulation of the Markov model had no effect on the model's conclusions. Conclusion In the Portuguese public healthcare system and under specific hypotheses, from a healthcare payer perspective, EF-CTX-guided cardioprotection for patients at risk of chemotherapy-related cardiotoxicity provides more QALYs at lower cost than UCP. | eng |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation | UIDB/00315/2020 | - |
dc.rights | openAccess | - |
dc.subject | Cancer survivorship | eng |
dc.subject | Heart failure | eng |
dc.subject | Cost-effectiveness | eng |
dc.subject | Cardioprotection | eng |
dc.title | Cost-effectiveness of cardio-oncology clinical assessment for prevention of chemotherapy-induced cardiotoxicity | eng |
dc.title.alternative | Custo-efetividade da avaliação clínica cárdio-oncológica para prevenção da cardiotoxicidade induzida por quimioterapia | pt |
dc.type | article | - |
dc.pagination | 475 - 483 | - |
dc.peerreviewed | yes | - |
dc.journal | Revista Portuguesa de Cardiologia | - |
dc.volume | 40 | - |
dc.number | 7 | - |
degois.publication.firstPage | 475 | - |
degois.publication.lastPage | 483 | - |
degois.publication.issue | 7 | - |
degois.publication.title | Cost-effectiveness of cardio-oncology clinical assessment for prevention of chemotherapy-induced cardiotoxicity | eng |
dc.date.updated | 2021-08-10T11:21:35Z | - |
dc.description.version | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.doi | 10.1016/j.repc.2020.09.012 | - |
dc.subject.fos | Domínio/Área Científica::Ciências Médicas::Medicina Clínica | por |
iscte.identifier.ciencia | https://ciencia.iscte-iul.pt/id/ci-pub-81880 | - |
iscte.alternateIdentifiers.wos | WOS:000671436400003 | - |
iscte.alternateIdentifiers.scopus | 2-s2.0-85106330322 | - |
Aparece nas coleções: | BRU-RN - Artigos em revistas científicas nacionais com arbitragem científica |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
article_81880.pdf | Versão Editora | 958,1 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.